-
1
-
-
79955748679
-
A review of tumour lysis syndrome with targeted therapies and the role of rasburicase
-
COI: 1:CAS:528:DC%2BC3MXotVGqtLs%3D, PID: 21501203
-
Bose P, Qubaiah O (2011) A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. J Clin Pharm Ther 36(3):299–329. doi:10.1111/j.1365-2710.2011.01260.x
-
(2011)
J Clin Pharm Ther
, vol.36
, Issue.3
, pp. 299-329
-
-
Bose, P.1
Qubaiah, O.2
-
2
-
-
79955884154
-
The tumor lysis syndrome
-
COI: 1:CAS:528:DC%2BC3MXlvF2jsrc%3D, PID: 21561350
-
Howard SC, Jones DP, Pui CH (2011) The tumor lysis syndrome. N Engl J Med 364(19):1844–1854. doi:10.1056/NEJMra0904569
-
(2011)
N Engl J Med
, vol.364
, Issue.19
, pp. 1844-1854
-
-
Howard, S.C.1
Jones, D.P.2
Pui, C.H.3
-
3
-
-
84890574505
-
Tumor lysis syndrome: new challenges and recent advances
-
PID: 24359983
-
Wilson FP, Berns JS (2014) Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis 21(1):18–26. doi:10.1053/j.ackd.2013.07.001
-
(2014)
Adv Chronic Kidney Dis
, vol.21
, Issue.1
, pp. 18-26
-
-
Wilson, F.P.1
Berns, J.S.2
-
4
-
-
77951686835
-
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
-
COI: 1:CAS:528:DC%2BC3cXns1eqt7c%3D, PID: 20331465
-
Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149(4):578–586. doi:10.1111/j.1365-2141.2010.08143.x
-
(2010)
Br J Haematol
, vol.149
, Issue.4
, pp. 578-586
-
-
Cairo, M.S.1
Coiffier, B.2
Reiter, A.3
Younes, A.4
TLS Expert Panel5
-
5
-
-
77950617707
-
An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome
-
PID: 20031331
-
Mughal TI, Ejaz AA, Foringer JR, Coiffier B (2010) An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 36(2):164–176. doi:10.1016/j.ctrv.2009.11.001
-
(2010)
Cancer Treat Rev
, vol.36
, Issue.2
, pp. 164-176
-
-
Mughal, T.I.1
Ejaz, A.A.2
Foringer, J.R.3
Coiffier, B.4
-
6
-
-
77952902915
-
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
-
COI: 1:CAS:528:DC%2BC3cXmsVSls7Y%3D, PID: 19962759
-
Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bolanos-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ (2010) Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res 34(7):877–882. doi:10.1016/j.leukres.2009.11.007
-
(2010)
Leuk Res
, vol.34
, Issue.7
, pp. 877-882
-
-
Karp, J.E.1
Blackford, A.2
Smith, B.D.3
Alino, K.4
Seung, A.H.5
Bolanos-Meade, J.6
Greer, J.M.7
Carraway, H.E.8
Gore, S.D.9
Jones, R.J.10
Levis, M.J.11
McDevitt, M.A.12
Doyle, L.A.13
Wright, J.J.14
-
7
-
-
84880854955
-
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) [abstract]
-
Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Miller TP, Gerecitano JF, Kipps TJ, Anderson MA, Huang DCS, Darden DE, Gressick LA, Nolan CE, Yang J, Busman TA, Graham AM, Cerri E, Enschede SH, Humerickhouse RA, Roberts AW (2013) Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) [abstract]. J Clin Oncol 31(15):7018
-
(2013)
J Clin Oncol
, vol.31
, Issue.15
, pp. 7018
-
-
Seymour, J.F.1
Davids, M.S.2
Pagel, J.M.3
Kahl, B.S.4
Wierda, W.G.5
Miller, T.P.6
Gerecitano, J.F.7
Kipps, T.J.8
Anderson, M.A.9
Huang, D.C.S.10
Darden, D.E.11
Gressick, L.A.12
Nolan, C.E.13
Yang, J.14
Busman, T.A.15
Graham, A.M.16
Cerri, E.17
Enschede, S.H.18
Humerickhouse, R.A.19
Roberts, A.W.20
more..
-
8
-
-
84907061764
-
ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete-response rate and durable disease control
-
Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Gerecitano JF, Kipps TJ, Anderson MA, Huang DCS, Rudersdorf N, Gressick LA, Montalvo NP, Yang J, Zhu M, Dunbar M, Cerri E, Enschede SH, Humerickhouse R, Roberts AW (2014) ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete-response rate and durable disease control. J Clin Oncol 32(15)
-
(2014)
J Clin Oncol
, vol.32
, Issue.15
-
-
Seymour, J.F.1
Davids, M.S.2
Pagel, J.M.3
Kahl, B.S.4
Wierda, W.G.5
Puvvada, S.6
Gerecitano, J.F.7
Kipps, T.J.8
Anderson, M.A.9
Huang, D.C.S.10
Rudersdorf, N.11
Gressick, L.A.12
Montalvo, N.P.13
Yang, J.14
Zhu, M.15
Dunbar, M.16
Cerri, E.17
Enschede, S.H.18
Humerickhouse, R.19
Roberts, A.W.20
more..
-
9
-
-
84925500858
-
ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase 1b study [abstract]
-
Ma S, Seymour JF, Lanasa MC, Kipps TJ, Barrientos JC, Davids MS, Mason-Bright T, Rudersdorf N, Yang J, Munasinghe W, Zhu M, Cerri E, Enschede SH, Humerickhouse R, Roberts AW (2014) ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase 1b study [abstract]. J Clin Oncol 32(15):7013
-
(2014)
J Clin Oncol
, vol.32
, Issue.15
, pp. 7013
-
-
Ma, S.1
Seymour, J.F.2
Lanasa, M.C.3
Kipps, T.J.4
Barrientos, J.C.5
Davids, M.S.6
Mason-Bright, T.7
Rudersdorf, N.8
Yang, J.9
Munasinghe, W.10
Zhu, M.11
Cerri, E.12
Enschede, S.H.13
Humerickhouse, R.14
Roberts, A.W.15
-
10
-
-
75749108938
-
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders
-
COI: 1:CAS:528:DC%2BC3cXivFartL4%3D, PID: 20008633
-
Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut EH, Baiocchi RA, Moran ME, Johnson AJ, Schaaf LJ, Grever MR, Byrd JC (2010) Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 28(3):418–423. doi:10.1200/JCO.2009.24.1570
-
(2010)
J Clin Oncol
, vol.28
, Issue.3
, pp. 418-423
-
-
Lin, T.S.1
Blum, K.A.2
Fischer, D.B.3
Mitchell, S.M.4
Ruppert, A.S.5
Porcu, P.6
Kraut, E.H.7
Baiocchi, R.A.8
Moran, M.E.9
Johnson, A.J.10
Schaaf, L.J.11
Grever, M.R.12
Byrd, J.C.13
-
11
-
-
77954499305
-
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
-
COI: 1:CAS:528:DC%2BC3cXhtlWjsL3E, PID: 20460644
-
Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR (2010) Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 95(7):1098–1105. doi:10.3324/haematol.2009.017103
-
(2010)
Haematologica
, vol.95
, Issue.7
, pp. 1098-1105
-
-
Blum, W.1
Phelps, M.A.2
Klisovic, R.B.3
Rozewski, D.M.4
Ni, W.5
Albanese, K.A.6
Rovin, B.7
Kefauver, C.8
Devine, S.M.9
Lucas, D.M.10
Johnson, A.11
Schaaf, L.J.12
Byrd, J.C.13
Marcucci, G.14
Grever, M.R.15
-
12
-
-
84883557418
-
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
-
COI: 1:CAS:528:DC%2BC3sXhtFWjurnN, PID: 23867058
-
Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM (2013) Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res 37(10):1195–1199. doi:10.1016/j.leukres.2013.06.006
-
(2013)
Leuk Res
, vol.37
, Issue.10
, pp. 1195-1199
-
-
Stephens, D.M.1
Ruppert, A.S.2
Maddocks, K.3
Andritsos, L.4
Baiocchi, R.5
Jones, J.6
Johnson, A.J.7
Smith, L.L.8
Zhao, Y.9
Ling, Y.10
Li, J.11
Phelps, M.A.12
Grever, M.R.13
Byrd, J.C.14
Flynn, J.M.15
-
13
-
-
79956036001
-
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms
-
COI: 1:CAS:528:DC%2BC3MXmtVGit7g%3D, PID: 21447728
-
Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD Sr, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S (2011) Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 17(10):3388–3397. doi:10.1158/1078-0432.CCR-10-2876
-
(2011)
Clin Cancer Res
, vol.17
, Issue.10
, pp. 3388-3397
-
-
Holkova, B.1
Perkins, E.B.2
Ramakrishnan, V.3
Tombes, M.B.4
Shrader, E.5
Talreja, N.6
Wellons, M.D.7
Hogan, K.T.8
Roodman, G.D.9
Coppola, D.10
Kang, L.11
Dawson, J.12
Stuart, R.K.13
Peer, C.14
Figg, W.D.15
Kolla, S.16
Doyle, A.17
Wright, J.18
Sullivan, D.M.19
Roberts, J.D.20
Grant, S.21
more..
-
14
-
-
84877099943
-
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2
-
COI: 1:CAS:528:DC%2BC3sXlsVCmsbs%3D, PID: 23515411
-
Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S (2013) A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res 19(7):1873–1883. doi:10.1158/1078-0432.CCR-12-2926
-
(2013)
Clin Cancer Res
, vol.19
, Issue.7
, pp. 1873-1883
-
-
Holkova, B.1
Supko, J.G.2
Ames, M.M.3
Reid, J.M.4
Shapiro, G.I.5
Perkins, E.B.6
Ramakrishnan, V.7
Tombes, M.B.8
Honeycutt, C.9
McGovern, R.M.10
Kmieciak, M.11
Shrader, E.12
Wellons, M.D.13
Sankala, H.14
Doyle, A.15
Wright, J.16
Roberts, J.D.17
Grant, S.18
-
15
-
-
34547650860
-
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia
-
COI: 1:CAS:528:DC%2BD2sXotlGqtLs%3D, PID: 17671131
-
Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD (2007) Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 13(15 Pt 1):4467–4473. doi:10.1158/1078-0432.CCR-07-0381
-
(2007)
Clin Cancer Res
, vol.13
, Issue.15
, pp. 4467-4473
-
-
Karp, J.E.1
Smith, B.D.2
Levis, M.J.3
Gore, S.D.4
Greer, J.5
Hattenburg, C.6
Briel, J.7
Jones, R.J.8
Wright, J.J.9
Colevas, A.D.10
-
16
-
-
84863678237
-
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
-
COI: 1:CAS:528:DC%2BC38XhtFCjtrnO, PID: 22614995
-
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30(18):2190–2196. doi:10.1200/JCO.2011.38.0402
-
(2012)
J Clin Oncol
, vol.30
, Issue.18
, pp. 2190-2196
-
-
Pro, B.1
Advani, R.2
Brice, P.3
Bartlett, N.L.4
Rosenblatt, J.D.5
Illidge, T.6
Matous, J.7
Ramchandren, R.8
Fanale, M.9
Connors, J.M.10
Yang, Y.11
Sievers, E.L.12
Kennedy, D.A.13
Shustov, A.14
-
17
-
-
84890827981
-
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
-
COI: 1:CAS:528:DC%2BC3sXhvFOqsr7P, PID: 24055823
-
Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA (2013) Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122(25):4129–4139. doi:10.1182/blood-2013-08-519413
-
(2013)
Blood
, vol.122
, Issue.25
, pp. 4129-4139
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Carpenter, R.O.3
Kassim, S.H.4
Rose, J.J.5
Telford, W.G.6
Hakim, F.T.7
Halverson, D.C.8
Fowler, D.H.9
Hardy, N.M.10
Mato, A.R.11
Hickstein, D.D.12
Gea-Banacloche, J.C.13
Pavletic, S.Z.14
Sportes, C.15
Maric, I.16
Feldman, S.A.17
Hansen, B.G.18
Wilder, J.S.19
Blacklock-Schuver, B.20
Jena, B.21
Bishop, M.R.22
Gress, R.E.23
Rosenberg, S.A.24
more..
-
18
-
-
84867427641
-
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma
-
COI: 1:CAS:528:DC%2BC38XhsVyhsbrP, PID: 23040437
-
Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS (2012) An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 12(5):310–318. doi:10.1016/j.clml.2012.08.003
-
(2012)
Clin Lymphoma Myeloma Leuk
, vol.12
, Issue.5
, pp. 310-318
-
-
Jagannath, S.1
Vij, R.2
Stewart, A.K.3
Trudel, S.4
Jakubowiak, A.J.5
Reiman, T.6
Somlo, G.7
Bahlis, N.8
Lonial, S.9
Kunkel, L.A.10
Wong, A.11
Orlowski, R.Z.12
Siegel, D.S.13
-
19
-
-
84867295563
-
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
-
COI: 1:CAS:528:DC%2BC38XhsFaksLbM, PID: 22833546
-
Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817–2825. doi:10.1182/blood-2012-05-425934
-
(2012)
Blood
, vol.120
, Issue.14
, pp. 2817-2825
-
-
Siegel, D.S.1
Martin, T.2
Wang, M.3
Vij, R.4
Jakubowiak, A.J.5
Lonial, S.6
Trudel, S.7
Kukreti, V.8
Bahlis, N.9
Alsina, M.10
Chanan-Khan, A.11
Buadi, F.12
Reu, F.J.13
Somlo, G.14
Zonder, J.15
Song, K.16
Stewart, A.K.17
Stadtmauer, E.18
Kunkel, L.19
Wear, S.20
Wong, A.F.21
Orlowski, R.Z.22
Jagannath, S.23
more..
-
20
-
-
84887007753
-
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
-
COI: 1:CAS:528:DC%2BC2cXotVKksLs%3D, PID: 23935022
-
Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S (2013) Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98(11):1753–1761. doi:10.3324/haematol.2013.089334
-
(2013)
Haematologica
, vol.98
, Issue.11
, pp. 1753-1761
-
-
Siegel, D.1
Martin, T.2
Nooka, A.3
Harvey, R.D.4
Vij, R.5
Niesvizky, R.6
Badros, A.Z.7
Jagannath, S.8
McCulloch, L.9
Rajangam, K.10
Lonial, S.11
-
21
-
-
84904054234
-
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
-
COI: 1:CAS:528:DC%2BC2cXitlSiurs%3D, PID: 24429497
-
Berenson JR, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, Bessudo A, Stampleman L, Gravenor D, Eshaghian S, Nassir Y, Swift RA, Vescio RA (2014) Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia 28(7):1529–1536. doi:10.1038/leu.2014.27
-
(2014)
Leukemia
, vol.28
, Issue.7
, pp. 1529-1536
-
-
Berenson, J.R.1
Hilger, J.D.2
Yellin, O.3
Dichmann, R.4
Patel-Donnelly, D.5
Boccia, R.V.6
Bessudo, A.7
Stampleman, L.8
Gravenor, D.9
Eshaghian, S.10
Nassir, Y.11
Swift, R.A.12
Vescio, R.A.13
-
22
-
-
84873545376
-
Dasatinib (versus imatinib) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of safety and efficacy by use of baseline medications in the DASISION trial [abstract]
-
Guilhot F, Kantarjian H, Shah NP, Hochhaus A, Brigid Bradley-Garelik M, Dejardin D, Cortes JE (2010) Dasatinib (versus imatinib) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of safety and efficacy by use of baseline medications in the DASISION trial [abstract]. Blood 116(21):2295
-
(2010)
Blood
, vol.116
, Issue.21
, pp. 2295
-
-
Guilhot, F.1
Kantarjian, H.2
Shah, N.P.3
Hochhaus, A.4
Brigid Bradley-Garelik, M.5
Dejardin, D.6
Cortes, J.E.7
-
23
-
-
79955765178
-
Dasatinib (Sprycel) and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): kinetic of response, resistance and prognostic significance [abstract]
-
Rousselot P, Cayuela JM, Hayette S, Recher C, Leguay T, Salanoubat C, Witz F, Alexis M, Hunault M, Janvier M, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Gokbuget N, Hoelzer D, Delannoy A, Bassan R, Ribera JM, Giebel S, Dombret H, Ottmann OG (2010) Dasatinib (Sprycel) and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): kinetic of response, resistance and prognostic significance [abstract]. Blood 116(21):172
-
(2010)
Blood
, vol.116
, Issue.21
, pp. 172
-
-
Rousselot, P.1
Cayuela, J.M.2
Hayette, S.3
Recher, C.4
Leguay, T.5
Salanoubat, C.6
Witz, F.7
Alexis, M.8
Hunault, M.9
Janvier, M.10
Agape, P.11
Berthou, C.12
Jourdan, E.13
Fernandes, J.14
Sutton, L.15
Banos, A.16
Reman, O.17
Lioure, B.18
Thomas, X.19
Ifrah, N.20
Gokbuget, N.21
Hoelzer, D.22
Delannoy, A.23
Bassan, R.24
Ribera, J.M.25
Giebel, S.26
Dombret, H.27
Ottmann, O.G.28
more..
-
24
-
-
84885373834
-
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
-
COI: 1:CAS:528:DC%2BC3sXht12ju73N, PID: 23949430
-
Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, Jou YM, Poon J, Small K, Bannerji R (2013) Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol 72(4):897–908. doi:10.1007/s00280-013-2249-z
-
(2013)
Cancer Chemother Pharmacol
, vol.72
, Issue.4
, pp. 897-908
-
-
Gojo, I.1
Sadowska, M.2
Walker, A.3
Feldman, E.J.4
Iyer, S.P.5
Baer, M.R.6
Sausville, E.A.7
Lapidus, R.G.8
Zhang, D.9
Zhu, Y.10
Jou, Y.M.11
Poon, J.12
Small, K.13
Bannerji, R.14
-
25
-
-
79955757849
-
Update on the phase I study of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): confirmation of clinical activity and feasibility of long-term administration [abstract]
-
Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC (2010) Update on the phase I study of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): confirmation of clinical activity and feasibility of long-term administration [abstract]. Blood 116(21):1396
-
(2010)
Blood
, vol.116
, Issue.21
, pp. 1396
-
-
Flynn, J.M.1
Jones, J.A.2
Andritsos, L.3
Blum, K.A.4
Johnson, A.J.5
Hessler, J.6
Wiley, E.7
Poon, J.8
Small, K.9
Statkevich, P.10
Grever, M.R.11
Bannerji, R.12
Byrd, J.C.13
-
26
-
-
84880858769
-
Rapid decrease in overall tumor burden on ibrutinib (PCI-32765) in CLL despite transient increase in ALC indicates a significant degree of treatment induced cell death [abstract]
-
Farooqui M, Aue G, Valdez J, Saba N, Herman SEM, Lipsky A, Bojanowski L, Wells A, Soto S, Liu D, Wiestner A (2012) Rapid decrease in overall tumor burden on ibrutinib (PCI-32765) in CLL despite transient increase in ALC indicates a significant degree of treatment induced cell death [abstract]. Blood 120(21):2899
-
(2012)
Blood
, vol.120
, Issue.21
, pp. 2899
-
-
Farooqui, M.1
Aue, G.2
Valdez, J.3
Saba, N.4
Herman, S.E.M.5
Lipsky, A.6
Bojanowski, L.7
Wells, A.8
Soto, S.9
Liu, D.10
Wiestner, A.11
-
27
-
-
84867843137
-
Combination of the Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase Ib/II study [abstract]
-
O’Brien SM, Barrientos JC, Flinn IW, Barr PM, Burger JA, Navarro T, James DF, Hedrick E, Friedberg JW, Brown JR (2012) Combination of the Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase Ib/II study [abstract]. J Clin Oncol 30(15):6515
-
(2012)
J Clin Oncol
, vol.30
, Issue.15
, pp. 6515
-
-
O’Brien, S.M.1
Barrientos, J.C.2
Flinn, I.W.3
Barr, P.M.4
Burger, J.A.5
Navarro, T.6
James, D.F.7
Hedrick, E.8
Friedberg, J.W.9
Brown, J.R.10
-
28
-
-
84901724050
-
A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
-
COI: 1:CAS:528:DC%2BC2cXhtVSgu7bO, PID: 24615778
-
Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND (2014) A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 123(22):3398–3405. doi:10.1182/blood-2013-11-537555
-
(2014)
Blood
, vol.123
, Issue.22
, pp. 3398-3405
-
-
Kahl, B.S.1
Spurgeon, S.E.2
Furman, R.R.3
Flinn, I.W.4
Coutre, S.E.5
Brown, J.R.6
Benson, D.M.7
Byrd, J.C.8
Peterman, S.9
Cho, Y.10
Yu, A.11
Godfrey, W.R.12
Wagner-Johnston, N.D.13
-
29
-
-
84901703641
-
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma
-
COI: 1:CAS:528:DC%2BC2cXhtVSgu7bP, PID: 24615776
-
Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123(22):3406–3413. doi:10.1182/blood-2013-11-538546
-
(2014)
Blood
, vol.123
, Issue.22
, pp. 3406-3413
-
-
Flinn, I.W.1
Kahl, B.S.2
Leonard, J.P.3
Furman, R.R.4
Brown, J.R.5
Byrd, J.C.6
Wagner-Johnston, N.D.7
Coutre, S.E.8
Benson, D.M.9
Peterman, S.10
Cho, Y.11
Webb, H.K.12
Johnson, D.M.13
Yu, A.S.14
Ulrich, R.G.15
Godfrey, W.R.16
Miller, L.L.17
Spurgeon, S.E.18
-
30
-
-
84901712964
-
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia
-
COI: 1:CAS:528:DC%2BC2cXhtVSgu7bN, PID: 24615777
-
Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR (2014) Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 123(22):3390–3397. doi:10.1182/blood-2013-11-535047
-
(2014)
Blood
, vol.123
, Issue.22
, pp. 3390-3397
-
-
Brown, J.R.1
Byrd, J.C.2
Coutre, S.E.3
Benson, D.M.4
Flinn, I.W.5
Wagner-Johnston, N.D.6
Spurgeon, S.E.7
Kahl, B.S.8
Bello, C.9
Webb, H.K.10
Johnson, D.M.11
Peterman, S.12
Li, D.13
Jahn, T.M.14
Lannutti, B.J.15
Ulrich, R.G.16
Yu, A.S.17
Miller, L.L.18
Furman, R.R.19
-
31
-
-
73949145763
-
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma
-
COI: 1:CAS:528:DC%2BD1MXhsFKkt7vN, PID: 19805688
-
Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol 27(32):5404–5409. doi:10.1200/JCO.2008.21.1169
-
(2009)
J Clin Oncol
, vol.27
, Issue.32
, pp. 5404-5409
-
-
Witzig, T.E.1
Wiernik, P.H.2
Moore, T.3
Reeder, C.4
Cole, C.5
Justice, G.6
Kaplan, H.7
Voralia, M.8
Pietronigro, D.9
Takeshita, K.10
Ervin-Haynes, A.11
Zeldis, J.B.12
Vose, J.M.13
-
32
-
-
81055123994
-
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
-
COI: 1:CAS:528:DC%2BC3MXhsFaksLvL, PID: 21937701
-
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL (2011) A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 118(19):5119–5125. doi:10.1182/blood-2011-07-362475
-
(2011)
Blood
, vol.118
, Issue.19
, pp. 5119-5125
-
-
Fehniger, T.A.1
Larson, S.2
Trinkaus, K.3
Siegel, M.J.4
Cashen, A.F.5
Blum, K.A.6
Fenske, T.S.7
Hurd, D.D.8
Goy, A.9
Schneider, S.E.10
Keppel, C.R.11
Wagner-Johnston, N.D.12
Carson, K.R.13
Bartlett, N.L.14
-
33
-
-
79952769640
-
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia
-
COI: 1:CAS:528:DC%2BC3MXmtVyrsL0%3D, PID: 21189385
-
Chen CI, Bergsagel PL, Paul H, Xu W, Lau A, Dave N, Kukreti V, Wei E, Leung-Hagesteijn C, Li ZH, Brandwein J, Pantoja M, Johnston J, Gibson S, Hernandez T, Spaner D, Trudel S (2011) Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 29(9):1175–1181. doi:10.1200/JCO.2010.29.8133
-
(2011)
J Clin Oncol
, vol.29
, Issue.9
, pp. 1175-1181
-
-
Chen, C.I.1
Bergsagel, P.L.2
Paul, H.3
Xu, W.4
Lau, A.5
Dave, N.6
Kukreti, V.7
Wei, E.8
Leung-Hagesteijn, C.9
Li, Z.H.10
Brandwein, J.11
Pantoja, M.12
Johnston, J.13
Gibson, S.14
Hernandez, T.15
Spaner, D.16
Trudel, S.17
-
34
-
-
80053350801
-
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
-
COI: 1:CAS:528:DC%2BC3MXhtlSqs7nI, PID: 21725050
-
Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O’Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A (2011) Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118(13):3489–3498. doi:10.1182/blood-2011-03-339077
-
(2011)
Blood
, vol.118
, Issue.13
, pp. 3489-3498
-
-
Badoux, X.C.1
Keating, M.J.2
Wen, S.3
Lee, B.N.4
Sivina, M.5
Reuben, J.6
Wierda, W.G.7
O’Brien, S.M.8
Faderl, S.9
Kornblau, S.M.10
Burger, J.A.11
Ferrajoli, A.12
-
35
-
-
84863115505
-
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
-
COI: 1:CAS:528:DC%2BC38Xis1amsLw%3D, PID: 21879809
-
Wendtner CM, Hillmen P, Mahadevan D, Buhler A, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA (2012) Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 53(3):417–423. doi:10.3109/10428194.2011.618232
-
(2012)
Leuk Lymphoma
, vol.53
, Issue.3
, pp. 417-423
-
-
Wendtner, C.M.1
Hillmen, P.2
Mahadevan, D.3
Buhler, A.4
Uharek, L.5
Coutre, S.6
Frankfurt, O.7
Bloor, A.8
Bosch, F.9
Furman, R.R.10
Kimby, E.11
Gribben, J.G.12
Gobbi, M.13
Dreisbach, L.14
Hurd, D.D.15
Sekeres, M.A.16
Ferrajoli, A.17
Shah, S.18
Zhang, J.19
Moutouh-de Parseval, L.20
Hallek, M.21
Heerema, N.A.22
Stilgenbauer, S.23
Chanan-Khan, A.A.24
more..
-
36
-
-
84875451856
-
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia
-
COI: 1:CAS:528:DC%2BC3sXjvVartr8%3D, PID: 23270003
-
Badoux XC, Keating MJ, Wen S, Wierda WG, O’Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A (2013) Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 31(5):584–591. doi:10.1200/JCO.2012.42.8623
-
(2013)
J Clin Oncol
, vol.31
, Issue.5
, pp. 584-591
-
-
Badoux, X.C.1
Keating, M.J.2
Wen, S.3
Wierda, W.G.4
O’Brien, S.M.5
Faderl, S.6
Sargent, R.7
Burger, J.A.8
Ferrajoli, A.9
-
37
-
-
84889099537
-
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study
-
COI: 1:CAS:528:DC%2BC3sXhsl2hsrfJ, PID: 24002500
-
Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, Zhang L, Cicero S, Fu T, Witzig TE (2013) Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 31(29):3688–3695. doi:10.1200/JCO.2013.49.2835
-
(2013)
J Clin Oncol
, vol.31
, Issue.29
, pp. 3688-3695
-
-
Goy, A.1
Sinha, R.2
Williams, M.E.3
Kalayoglu Besisik, S.4
Drach, J.5
Ramchandren, R.6
Zhang, L.7
Cicero, S.8
Fu, T.9
Witzig, T.E.10
-
38
-
-
84881109532
-
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial
-
COI: 1:CAS:528:DC%2BC3sXosFOhsrc%3D, PID: 23731832
-
Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 49(13):2869–2876. doi:10.1016/j.ejca.2013.04.029
-
(2013)
Eur J Cancer
, vol.49
, Issue.13
, pp. 2869-2876
-
-
Morschhauser, F.1
Fitoussi, O.2
Haioun, C.3
Thieblemont, C.4
Quach, H.5
Delarue, R.6
Glaisner, S.7
Gabarre, J.8
Bosly, A.9
Lister, J.10
Li, J.11
Coiffier, B.12
-
39
-
-
84857099282
-
Encouraging activity of obinutuzumab (GA101) monotherapy in relapsed/refractory aggressive non-Hodgkin’s lymphoma: results from a phase II study (BO20999) [abstract]
-
Morschhauser F, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, Lamy T, Milpied N, Gouill SL, Feugier P, Wenger MK, Wassner-Fritsch E, Asikanius E, Salles GA (2011) Encouraging activity of obinutuzumab (GA101) monotherapy in relapsed/refractory aggressive non-Hodgkin’s lymphoma: results from a phase II study (BO20999) [abstract]. Blood 118(21):3655
-
(2011)
Blood
, vol.118
, Issue.21
, pp. 3655
-
-
Morschhauser, F.1
Cartron, G.2
Thieblemont, C.3
Solal-Celigny, P.4
Haioun, C.5
Bouabdallah, R.6
Lamy, T.7
Milpied, N.8
Gouill, S.L.9
Feugier, P.10
Wenger, M.K.11
Wassner-Fritsch, E.12
Asikanius, E.13
Salles, G.A.14
-
40
-
-
84896467578
-
Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase Ib GALTON trial (GAO4779g) [abstract]
-
Brown JR, O’Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ (2013) Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase Ib GALTON trial (GAO4779g) [abstract]. Blood 122(21):523
-
(2013)
Blood
, vol.122
, Issue.21
, pp. 523
-
-
Brown, J.R.1
O’Brien, S.2
Kingsley, C.D.3
Eradat, H.4
Pagel, J.M.5
Lymp, J.6
Hirata, J.7
Kipps, T.J.8
-
41
-
-
84861830510
-
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
-
COI: 1:CAS:528:DC%2BC38XhtVWjsrfN, PID: 22438256
-
Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, Frances-Lasserre S, Carlile DJ, Crump M (2012) A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 119(22):5118–5125. doi:10.1182/blood-2012-02-408773
-
(2012)
Blood
, vol.119
, Issue.22
, pp. 5118-5125
-
-
Sehn, L.H.1
Assouline, S.E.2
Stewart, D.A.3
Mangel, J.4
Gascoyne, R.D.5
Fine, G.6
Frances-Lasserre, S.7
Carlile, D.J.8
Crump, M.9
-
42
-
-
84861835530
-
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
-
COI: 1:CAS:528:DC%2BC38XhtVWjsrfJ, PID: 22431570
-
Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G (2012) Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119(22):5126–5132. doi:10.1182/blood-2012-01-404368
-
(2012)
Blood
, vol.119
, Issue.22
, pp. 5126-5132
-
-
Salles, G.1
Morschhauser, F.2
Lamy, T.3
Milpied, N.4
Thieblemont, C.5
Tilly, H.6
Bieska, G.7
Asikanius, E.8
Carlile, D.9
Birkett, J.10
Pisa, P.11
Cartron, G.12
-
43
-
-
84907698941
-
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
-
COI: 1:CAS:528:DC%2BC2cXhvVGrtr%2FN, PID: 25143487
-
Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G, Wenger M, Wassner-Fritsch E, Hallek M (2014) Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood 124(14):2196–2202. doi:10.1182/blood-2014-07-586610
-
(2014)
Blood
, vol.124
, Issue.14
, pp. 2196-2202
-
-
Cartron, G.1
de Guibert, S.2
Dilhuydy, M.S.3
Morschhauser, F.4
Leblond, V.5
Dupuis, J.6
Mahe, B.7
Bouabdallah, R.8
Lei, G.9
Wenger, M.10
Wassner-Fritsch, E.11
Hallek, M.12
-
44
-
-
84891442057
-
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study
-
COI: 1:CAS:528:DC%2BC3sXhsV2gu7vI, PID: 23835718
-
Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, Salles GA (2013) Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 31(23):2912–2919. doi:10.1200/JCO.2012.46.9585
-
(2013)
J Clin Oncol
, vol.31
, Issue.23
, pp. 2912-2919
-
-
Morschhauser, F.A.1
Cartron, G.2
Thieblemont, C.3
Solal-Celigny, P.4
Haioun, C.5
Bouabdallah, R.6
Feugier, P.7
Bouabdallah, K.8
Asikanius, E.9
Lei, G.10
Wenger, M.11
Wassner-Fritsch, E.12
Salles, G.A.13
-
45
-
-
84885428115
-
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma
-
COI: 1:CAS:528:DC%2BC3sXhs1WntLrF, PID: 24032456
-
Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, Lisby S, Study i (2013) A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol 163(3):334–342. doi:10.1111/bjh.12537
-
(2013)
Br J Haematol
, vol.163
, Issue.3
, pp. 334-342
-
-
Coiffier, B.1
Radford, J.2
Bosly, A.3
Martinelli, G.4
Verhoef, G.5
Barca, G.6
Davies, A.7
Decaudin, D.8
Gallop-Evans, E.9
Padmanabhan-Iyer, S.10
Van Eygen, K.11
Wu, K.L.12
Gupta, I.V.13
Lin, T.S.14
Goldstein, N.15
Jewell, R.C.16
Winter, P.17
Lisby, S.18
Study, I19
-
46
-
-
84877726177
-
Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL): results of a phase II trial [abstract]
-
Ferrajoli A, Falchi L, O’Brien S, Wierda W, Faderl S, Smith SC, Ayala AB, Kantarjian HM, Keating MJ (2012) Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL): results of a phase II trial [abstract]. Blood 120(21):720
-
(2012)
Blood
, vol.120
, Issue.21
, pp. 720
-
-
Ferrajoli, A.1
Falchi, L.2
O’Brien, S.3
Wierda, W.4
Faderl, S.5
Smith, S.C.6
Ayala, A.B.7
Kantarjian, H.M.8
Keating, M.J.9
-
47
-
-
84906056010
-
Clinical profile of single-agent modified-release oprozomib tablets in patients (PTS) with hematologic malignancies: updated results from a multicenter, open-label, dose escalation phase 1B/2 study [abstract]
-
Ghobrial IM, Kaufman JL, Siegel DS, Vij R, Badros A, Neuman L, Wong H, Anderl J, Savona M (2013) Clinical profile of single-agent modified-release oprozomib tablets in patients (PTS) with hematologic malignancies: updated results from a multicenter, open-label, dose escalation phase 1B/2 study [abstract]. Blood 122(21):3184
-
(2013)
Blood
, vol.122
, Issue.21
, pp. 3184
-
-
Ghobrial, I.M.1
Kaufman, J.L.2
Siegel, D.S.3
Vij, R.4
Badros, A.5
Neuman, L.6
Wong, H.7
Anderl, J.8
Savona, M.9
-
48
-
-
84878106761
-
The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study [abstract]
-
Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF, Darden DE, Nolan CE, Gressick LA, Yang J, Chyla BJ, Busman TA, Graham AM, Cerri E, Enschede SH, Humerickhouse RA, Seymour JF (2012) The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study [abstract]. Blood 120(21):304
-
(2012)
Blood
, vol.120
, Issue.21
, pp. 304
-
-
Davids, M.S.1
Roberts, A.W.2
Anderson, M.A.3
Pagel, J.M.4
Kahl, B.S.5
Gerecitano, J.F.6
Darden, D.E.7
Nolan, C.E.8
Gressick, L.A.9
Yang, J.10
Chyla, B.J.11
Busman, T.A.12
Graham, A.M.13
Cerri, E.14
Enschede, S.H.15
Humerickhouse, R.A.16
Seymour, J.F.17
-
49
-
-
84885421557
-
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) [abstract]
-
Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG, Anderson MA, Darden DE, Nolan CE, Gressick LA, Yang J, Chyla BJ, Busman TA, Graham AM, Cerri E, Enschede SH, Humerickhouse RA, Roberts AW (2013) Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) [abstract]. J Clin Oncol 31(15):8520
-
(2013)
J Clin Oncol
, vol.31
, Issue.15
, pp. 8520
-
-
Davids, M.S.1
Seymour, J.F.2
Gerecitano, J.F.3
Kahl, B.S.4
Pagel, J.M.5
Wierda, W.G.6
Anderson, M.A.7
Darden, D.E.8
Nolan, C.E.9
Gressick, L.A.10
Yang, J.11
Chyla, B.J.12
Busman, T.A.13
Graham, A.M.14
Cerri, E.15
Enschede, S.H.16
Humerickhouse, R.A.17
Roberts, A.W.18
-
50
-
-
84910091007
-
Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses [abstract]
-
Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG, Anderson MA, Rudersdorf N, Gressick LA, Montalvo NP, Yang J, Zhu M, Dunbar M, Cerri E, Enschede SH, Humerickhouse R, Roberts AW (2014) Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses [abstract]. J Clin Oncol 32(15):8522
-
(2014)
J Clin Oncol
, vol.32
, Issue.15
, pp. 8522
-
-
Davids, M.S.1
Seymour, J.F.2
Gerecitano, J.F.3
Kahl, B.S.4
Pagel, J.M.5
Wierda, W.G.6
Anderson, M.A.7
Rudersdorf, N.8
Gressick, L.A.9
Montalvo, N.P.10
Yang, J.11
Zhu, M.12
Dunbar, M.13
Cerri, E.14
Enschede, S.H.15
Humerickhouse, R.16
Roberts, A.W.17
-
51
-
-
84907061764
-
ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): high complete-response rate and durable disease control [abstract]
-
Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Gerecitano JF, Kipps TJ, Anderson MA, Huang DCS, Rudersdorf N, Gressick LA, Montalvo NP, Yang J, Zhu M, Dunbar M, Cerri E, Enschede SH, Humerickhouse R, Roberts AW (2014) ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): high complete-response rate and durable disease control [abstract]. J Clin Oncol 32(15):7015
-
(2014)
J Clin Oncol
, vol.32
, Issue.15
, pp. 7015
-
-
Seymour, J.F.1
Davids, M.S.2
Pagel, J.M.3
Kahl, B.S.4
Wierda, W.G.5
Puvvada, S.6
Gerecitano, J.F.7
Kipps, T.J.8
Anderson, M.A.9
Huang, D.C.S.10
Rudersdorf, N.11
Gressick, L.A.12
Montalvo, N.P.13
Yang, J.14
Zhu, M.15
Dunbar, M.16
Cerri, E.17
Enschede, S.H.18
Humerickhouse, R.19
Roberts, A.W.20
more..
-
52
-
-
85031960490
-
-
Cortez M (2013) AbbVie suspends five clinical trials of leukemia therapy. Bloomberg Business. Accessed April 29 2015
-
Cortez M (2013) AbbVie suspends five clinical trials of leukemia therapy. Bloomberg Business. http://www.bloomberg.com/news/articles/2013-02-15/abbvie-suspends-five-clinical-trials-of-leukemia-therapy. Accessed April 29 2015
-
-
-
-
53
-
-
36849068944
-
Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia
-
PID: 17971612
-
Moutouh-de Parseval LA, Weiss L, DeLap RJ, Knight RD, Zeldis JB (2007) Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 25(31):5047. doi:10.1200/JCO.2007.14.2141
-
(2007)
J Clin Oncol
, vol.25
, Issue.31
, pp. 5047
-
-
Moutouh-de Parseval, L.A.1
Weiss, L.2
DeLap, R.J.3
Knight, R.D.4
Zeldis, J.B.5
-
54
-
-
84959494555
-
-
National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas. Version 5.2014. Accessed November 1 2014
-
National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas. Version 5.2014. http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed November 1 2014
-
-
-
-
55
-
-
84940108100
-
Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy J Oncol Pharm Pract:[Epub ahead of print]
-
Fallon MJ, Heck JN (2014) Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy J Oncol Pharm Pract:[Epub ahead of print]. doi: 10.1177/1078155214533368
-
(2014)
doi: 10.1177/1078155214533368
-
-
Fallon, M.J.1
Heck, J.N.2
-
56
-
-
85031953295
-
-
Inc., North Wales, PA
-
TREANDA (bendamustine hydrochloride). Full Prescribing Information, Teva Pharmaceuticals USA, Inc., North Wales, PA, 2015
-
(2015)
Teva Pharmaceuticals USA
-
-
-
57
-
-
84874825923
-
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol
-
COI: 1:CAS:528:DC%2BC3sXjsFektLk%3D, PID: 23300276
-
Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MA (2013) A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin Cancer Res 19(5):1269–1280. doi:10.1158/1078-0432.CCR-12-1092
-
(2013)
Clin Cancer Res
, vol.19
, Issue.5
, pp. 1269-1280
-
-
Ji, J.1
Mould, D.R.2
Blum, K.A.3
Ruppert, A.S.4
Poi, M.5
Zhao, Y.6
Johnson, A.J.7
Byrd, J.C.8
Grever, M.R.9
Phelps, M.A.10
|